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Background/aim: Ankaferd hemostat (ABS; Ankaferd blood stopper, İstanbul, Turkey) is a prohemostatic agent affecting erythrocytes.
The hemostatic action of ABS depends upon fibrinogen gamma chain, prothrombin, and red blood cells. The aim of this study was to
assess the effects of ABS on erythrocyte aggregation via hemorheological analyses.
Materials and methods: To measure erythrocyte aggregation, blood samples were obtained from healthy, nonsmoker volunteers who
had not taken any medication in the previous 10 days. One mL of blood was placed into the laser-assisted optical rotational cell analyzer
(LORCA), into the chamber formed by the gap between two concentric glass cylinders. The solution prepared with ABS and saline was
added to blood in incremental amounts of 10 µL, 20 µL, 30 µL, 40 µL, 50 µL, 60 µL, 70 µL, and 100 µL. Erythrocyte aggregation was
determined by laser-assisted optical rotational cell analyzer at 37 °C.
Results: AMP was found to be 17.7 ± 2.1 au in the blood without ABS, whereas it was lower in the blood with ABS. AMP was 16.0 ±
3.3 in the ABS-added blood group. RBC aggregates did not form faster when cells contacted ABS. The t t½ value was 4.6 ± 2.6 in the
ABS-added blood group and 1.9 ± 0.20 in the control group. Aggregation was faster in the control group (P = 0.03). AI, which is a
combination of AMP and t½, was lowered in the ABS group (48.7 ± 12.3) compared to the control group (65.8 ± 1.6) (P = 0.02). It was
notable that the γIsc max (sec-1) value of the control was higher (200 ± 106) than the ABS-added blood group (141 ± 51.0).
Conclusion: ABS has antierythroid aggregation effect. ABS inhibits pathological aggregation of red blood cells. Antithrombotic clinical
effects of ABS may be ascribed to the antierythroid aggregan actions of the drug.
Key words: Ankaferd Hemostat, erythrocyte aggregation, hemorheology

1. Introduction
Ankaferd hemostat (ABS; Ankaferd blood stopper,
İstanbul, Turkey) is a hemostatic agent affecting red blood
cell (RBC) physiology (1). Ankaferd has been used as
a hemostatic agent for the management of the distinct
types of clinical bleedings (2). ABS is effective on cellular
hemostasis. The hemostatic effect of ABS depends upon
the quick promotion of a protein network, particularly
fibrinogen gamma, in relation to the erythrocyte
aggregation (1). ABS has been tested in numerous clinical
trials. Thrombosis associated with ABS has not been
observed in any clinical study. On the contrary, antiplatelet
and antithrombin effects of ABS have been demonstrated
(3). The effects of ABS on RBC aggregation have not been
previously investigated.
The viscosity of the blood is a measure of its inner
resistance to flow. It is an important factor in the

cardiovascular system circulation (4,5). Erythrocyte
deformability, erythrocyte aggregation, plasma viscosity,
and hematocrit level determine the blood viscosity.
Erythrocyte deformability is the capability of RBCs to
modify shape as they move through the circulation. The
viscosity and resistance of the blood flow are decreased by
erythrocyte deformability. This characteristic is especially
significant during the transition across capillaries smaller
than the diameter of erythrocytes (6). In contrast to the
platelets, RBCs aggregate spontaneously. Under the normal
conditions, RBC aggregates to be similar to stacks of coins.
This phenomenon was called as rouleaux (7). Zijlstra,
first defined the technique for the quantification of RBC
aggregation procedure by measuring the decrements in the
light backscatter and suggested the name ‘syllectometry’
(8). Their principles had been confirmed in further studies
(9). The syllectometry principle for measuring the RBC

* Correspondence: rafiyesarigul@gmail.com

356

This work is licensed under a Creative Commons Attribution 4.0 International License.

ÇİFTÇİLER et al. / Turk J Med Sci
aggregation has been used since then by many researchers
and is also applied as the laser-assisted optical rotational
cell analyzer (LORCA) (10).
ABS could inhibit pathological accumulation of
circulating blood cells so that vessel thrombosis may not
occur in the presence of ABS-induced antihemorrhagic
effects. The hemostatic action of ABS depends upon the
fibrinogen gamma chain, prothrombin, and red blood
cells. The aim of this study was to assess the effects of ABS
on erythrocyte aggregation via hemorheological analyses.
Elucidation of the interrelationships between ABS and
RBC physiology is important for the enlightening of the
pharmacobiological action of the drug particularly for its
clinical applications.
2. Materials and methods
2.1. Instrument description
The basic instruments were the laser, thermostated
measuring system, stepper motor, and video camera. The
laboratory setup consisted further of an IBM-compatible
PC plus printer.
2.2. Sample preparation
Human blood was anticoagulated with EDTA. The solution
was prepared with ABS and saline. The mixing ratio was
ABS/saline = 1/10. ABS alone could not be used because
the clot was formed when contacted with blood. Prior
to each measurement, blood samples were oxygenated
for 10–15 min to mimic the arterial blood composition.
Following oxygenation, 1 mL of whole blood was placed
into the chamber formed between the glass cylinders. The
solution prepared with ABS and saline was added to blood
in incremental amounts of 10 µL, 20 µL, 30 µL, 40 µL, 50
µL, 60 µL, 70 µL, and 100 µL. Informed consent for the
procedure was obtained from blood donors for this study.
2.3. Erythrocyte aggregation
Human RBC aggregation was investigated with an
automatic hemorheological analyzer. Erythrocyte
aggregation was determined within 1 h of the withdrawal
of blood from the volunteer, since erythrocyte aggregation
changes with time. Aggregation parameters were measured
by LORCA at 37 °C. Following oxygenation, 1 mL of whole
blood was placed into the chamber formed between the
glass cylinders. The solution prepared with ABS and saline
was added to blood in incremental amounts of 10 µL, 20
µL, 30 µL, 40 µL, 50 µL, 60 µL, 70 µL, 80 µL, 90 µL, and
100 µL. Aggregation indices were measured with twenty
different ABS quantities and two control groups. Since
whole blood does not allow the laser beam to traverse
through the chambers as in erythrocyte aggregation
measurement depends on backscattered light. With the
aggregation of erythrocytes, the intensity of this laser light

decreases, and this decrease is recorded as a syllectogram.
LORCA software calculates the amplitude (AMP,
representing the total extent of aggregation, measured in
au unit), aggregation half-time (t½, time that passes until
the peak intensity is reduced by half, reflects the kinetics
of aggregation, represented in seconds), γIsc max (sec−1)
(threshold shear rate needed to prevent aggregation)
and aggregation index which is an index associated both
AMP and t½ parameters in its formula (AI, a larger index
represents greater and/or faster aggregation, shown in %
as unit) and from this syllectogram (7,10,11). An increase
in AMP and a decrease in t½ increase AI were observed.
2.4. Statistical analysis
Statistical analyses were performed using the SPSS
software version 25. The variables were investigated
using visual (histograms, probability plots) and analytical
methods (Kolmogorow–Simirnov/Shapiro–Wilk’s test) to
determine whether or not they are normally distributed.
Data were analyzed separately with Mann–Whitney U
test and also with independent samples Student’s t test in
order to test the validity of data with regards to parametric
assumptions.
3. Results
3.1. Effects of ABS on erythrocyte aggregation
Results ABS application lowered AMP compared to blood
without ABS. AMP is an indicator of the magnitude of
erythrocyte aggregation and its value was found to be 17.7
± 2.1 au in the blood without ABS, whereas it was lower
in the blood with ABS. AMP was 16.0 ± 3.3 in the ABSadded blood group. Statistical difference was not observed
between the two groups (P = 0.39).
The kinetics of the aggregation process is also expressed by
the half-time (t½) value. Because t½ is the time necessary
to reach 50% of complete aggregation level, a lower t½
reflects a faster aggregation process. RBC aggregates do
not form faster when cells contact ABS. The t½ value was
4.6 ± 2.6 in the ABS-added blood group and 1.9 ± 0.20 in
the control group. Aggregation was faster in control group
(P = 0.03).
AI, which is a combination of AMP and t½, is lower in the
ABS group (48.7 ± 12.3) compared to that in the control
group (65.8 ± 1.6) (P = 0.02). Aggregation parameters are
given in Figure. γIsc max (sec−1) is threshold the shear
rate needed to prevent aggregation. The measured γIsc
max (sec−1) that prevented aggregation was presented in
Table. It was notable that the γIsc max (sec−1) value of the
control was higher (200 ± 106) than that of the ABS-added
blood group (141 ± 51.0). However, it was not statistically
significant (P = 0.32). Aggregation parameters are shown
in Table.
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Figure. Effect of Ankaferd hemostat (ABS) on erythrocyte aggregation index (AI),
amplitude (A) and aggregation half-time (t½).

Table. Effect of Ankaferd hemostat (ABS) on red blood cell (RBC) aggregation indices.
ABS-added blood

Blood without ABS (control)

P

AMP (au)

16.0 ± 3.3

17.7 ± 2.1

0.39

t½ (sec)

4.6 ± 2.6

1.9 ± 0.20

0.03

AI (%)

48.7 ± 12.3

65.8 ± 1.6

0.02

141 ± 51.0

200 ±106

0.32

γIsc max (sec )
−1

Abbreviations: AI: aggregation index; AMP: amplitude; t½: aggregation for half-time;
γIsc max (sec−1): threshold shear rate needed to prevent aggregation.

4. Discussion
In this study, the antierythroid aggregation effects of ABS
have been described. ABS inhibits pathological aggregation
in red blood cells so that thrombosis may not take place in
the presence of antihemorrhagic effect of ABS on clinical
grounds. Previously, antiplatelet and antithrombin effects
of ABS were already shown (3). The effects of ABS on RBC
aggregation may be implicated in the antithrombin effects
of ABS.
The hemostatic action of ABS depends upon fibrinogen
gamma chain, prothrombin, and red blood cells (1).
Rather than affecting an individual clotting factor, this
protein network affects the entire physiological hemostatic
procedure that controls bleeding (2,12). Prohemostatic
and antithrombin activities of ABS were shown to be
associated with fibrinogen gamma chain and prothrombin
with functional proteomic analyzes. Fibrinogen gamma
chain was shown to be decreased at first and then increased
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during the hemostatic activity of ABS in plasma and
serum samples based on functional proteomic analyses. In
addition to the prothrombin levels in serum that decreased
first and thereafter enhanced following the generation of
the ABS-induced protein network. Effects of ABS on these
two molecules seem to be associated with pro-hemostatic
and anti-thrombin activities of the hemostatic agent (13).
Egin et al. suggested that ABS-induced antihemorrhagic
effects seem to happen by the ‘balanced hemostasis’ via
preventing thrombin-induced thrombotic events in the
vascular endothelial space (3). The antithrombin activity
of ABS is important especially in cardiac surgery. ABS
was shown not to have the risk of thrombin-induced
thrombotic complications by cardiac surgeons during
open heart surgery (14–17). The demonstration of the
antierythroid aggregation of ABS is an important result in
terms of the antihemorrhagic effect that does not create a
risk of thrombosis.
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Koluman et al. investigated the fate of antioxidant
ingredients of ABS when exposed to synthetic gastric fluid.
Furthermore, they demonstrated the safety profile for ABS
focusing on the presence of pesticides, mycotoxins, heavy
metals, genetically modified organisms, and dioxin. Time
of Flight Mass Spectroscopy spectra showed the presence
of several antioxidant molecules (such as tocotrienols,
members of the vitamin E family, tryptophan, estriol,
galangin, apigenin, oenin, 3,4-divanillyltetrahydrofuran,
tertiary
butylhydroquinone,
thymol,
butylated
hydroxyanisole, butylated hydroxytoluene, lycopene,
enoxolone/glycyrrhetinic acid or glycyrrhetic acid, and
tomatine), which may have clinical implications in the
pharmacological activities of ABS. They showed that
the concentrations of the antioxidants and other specific
molecules in the ABS were not affected after the exposure
to the synthetic gastric fluid (18).
Akar et al. demonstrated the presence of Fe (III) ions
and, at very low concentrations, some other trace elements
inside ABS. Human fibrinogen immediately recognizes

iron. Thus, iron can play an important role in the ABS
related cellular hemostasis located in the junction of RBC–
fibrinogen interactions (19). The antithrombotic effect of
ABS may be associated with the presence of Fe (III) ions.
Although with different pathogenic mechanisms, both
iron deficiency and overload have been associated with
an increased thrombotic risk in experimental and clinical
studies (20). Future studies should focus on the association
between ABS-related high iron content, fibrinogen
gamma, and vital erythroid aggregation. Likewise, more
studies are needed to elucidate the pharmacophysiology
of the antithrombotic effect of ABS. Antiplatelet and
antithrombin effects of ABS may also be related to
antierythroid aggregation effects that we have found in the
present study.
In conclusion, ABS has an antierythroid aggregation
effect. ABS could inhibit pathological aggregation of
red blood cells so that thrombosis may not occur in the
presence of the antihemorrhagic effects of ABS.
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